{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:43:32Z","timestamp":1747151012728,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Hepatitis C virus (HCV) infection among drug users presents an important public health problem; however, little recognition and few approaches to address this issue in Japan. This study was conducted to investigate the current disease status by assessing anti\u2010HCV antibody (Ab) seroprevalence among people who inject drugs (PWIDs) and people who use drugs (PWUDs) in Hiroshima, Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a psychiatric single\u2010site chart review in patients with drug abuse problems in the Hiroshima region. The primary outcome was anti\u2010HCV Ab prevalence among PWIDs who underwent anti\u2010HCV Ab testing. The secondary outcomes included the prevalence of anti\u2010HCV Ab among PWUDs who underwent anti\u2010HCV Ab testing and the proportion of patients who underwent anti\u2010HCV Ab examination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 222 PWUD patients were enrolled. Among these, 16 patients (7.2%) had records of injection drug use (PWIDs). Eleven (68.8%) of the 16 PWIDs received anti\u2010HCV Ab tests, and 4 (36.4%, 4\/11) were anti\u2010HCV Ab\u2010positive. Among 222 PWUDs, 126 (56.8%) patients received anti\u2010HCV Ab tests, and 57 of these patients (45.2%, 57\/126) were anti\u2010HCV Ab\u2010positive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of anti\u2010HCV Ab among PWIDs and PWUDs who visited the study site was higher than the general population, which was 2.2% among hospitalized patients between May 2018 and November 2019. Considering the World Health Organization's (WHO) elimination goal and recent advances in HCV treatment, patients with drug abuse experience should be encouraged to take HCV tests and consult hepatologists for further investigations and treatment if they are positive for anti\u2010HCV Ab.<\/jats:p><\/jats:sec>","DOI":"10.1002\/npr2.12346","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:31:55Z","timestamp":1684287115000},"page":"521-531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A single site study to investigate the current prevalence of anti\u2010hepatitis C virus antibody among substance use disorder patients in Hiroshima\u2014Insufficient testing and diagnosis"],"prefix":"10.1002","volume":"43","author":[{"given":"Ariyuki","family":"Kagaya","sequence":"first","affiliation":[{"name":"KONUMA Memorial Institute of Addiction and Mental Health  Hiroshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Nagaoki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Mazda Hospital, Mazda Motor Corporation  Hiroshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-988X","authenticated-orcid":false,"given":"Satomi","family":"Shimura","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Kawana","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[{"name":"Department of Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences Hiroshima University  Hiroshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organization [Internet].Final global health sector strategies on respectively HIV viral hepatitis and sexually transmitted infections 2022\u20132030. [cited 2022 Oct 20]. Available from:https:\/\/www.who.int\/teams\/global\u2010hiv\u2010hepatitis\u2010and\u2010stis\u2010programmes\/strategies\/global\u2010health\u2010sector\u2010strategies\/developing\u2010ghss\u20102022\u20102030"},{"key":"e_1_2_12_3_1","unstructured":"European Association for Study of the Liver [Internet].Policy statement on drug use and the global hepatitis C elimination goal. [cited 2022 Oct 20]. Available from:https:\/\/easl.eu\/publication\/policy\u2010statement\u2010drug\u2010use\u2010hepc\/"},{"key":"e_1_2_12_4_1","unstructured":"American Association for the Study of Liver Diseases Infectious Diseases Society of America [Internet].HCV guidance: Recommendations for testing managing and treating hepatitis C. [cited 2022 Oct 20]. Available from:https:\/\/www.hcvguidelines.org\/unique\u2010populations\/key"},{"key":"e_1_2_12_5_1","unstructured":"Centers for Disease Control and Prevention [Internet].Viral hepatitis. [cited 2022 Oct 20]. Available from:https:\/\/www.cdc.gov\/hepatitis\/index.htm"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12376"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13417"},{"key":"e_1_2_12_8_1","unstructured":"Ministry of Health Labour and Welfare [Internet].The results of viral hepatitis testing from 2002 to 2006. (in Japanese). [cited 2022 Oct 20]. Available from:https:\/\/www.mhlw.go.jp\/houdou\/2007\/10\/h1003\u20101.html"},{"key":"e_1_2_12_9_1","unstructured":"Ministry of Health Labour and Welfare [Internet].The 24th council for promotion of measures against hepatitis (in Japanese). [cited 2022 Oct 20]. Available from:https:\/\/www.mhlw.go.jp\/stf\/newpage_08387.html"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz185"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10019-z"},{"key":"e_1_2_12_12_1","unstructured":"WadaK.\u201cResearch project on HIV infection and behavior monitoring among drug abusers and addicts\u201d Research program for counter measures of AIDS Health and labor sciences research grant. (in Japanese).2017."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.019"},{"key":"e_1_2_12_14_1","unstructured":"Hiroshima Prefecture [Internet].Press release about an agreement for promoting countermeasures against viral hepatitis between Hiroshima prefecture Hiroshima University and AbbVie. (in Japanese). [cited 2022 Oct 20]. Available from:https:\/\/www.pref.hiroshima.lg.jp\/site\/kanenshinsei\/hepacontract.html"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14982"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2105181"},{"key":"e_1_2_12_17_1","unstructured":"SatakeH.[Internet]. \u201cFact\u2010finding survey on hepatitis C virus infection at medical institutions\u201d Health and labour sciences research grant Research on hepatitis. (in Japanese). [cited 2022 Oct 20]. Available from:https:\/\/mhlw\u2010grants.niph.go.jp\/system\/files\/2019\/192161\/201921003A_upload\/201921003A0005.pdf"},{"key":"e_1_2_12_18_1","unstructured":"TanakaJ SakamuneK KurisuA AkitaT OhisaM SugiyamaA.[Internet]. \u201cFact\u2010finding survey on hepatitis examinations\u201d Health and labour sciences research grant Research on hepatitis. (in Japanese). [cited 10 Mar 2023]. Available from:https:\/\/mhlw\u2010grants.niph.go.jp\/system\/files\/2017\/172131\/201720001A_upload\/201720001A0027.pdf"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100580"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108116"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.11.026"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0151"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01166-3"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.012"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21-4119"},{"key":"e_1_2_12_26_1","unstructured":"National Institute of Mental Health [Internet].Research Report. (in Japanese). [cited 2023 Apr 20]. Available from:https:\/\/www.ncnp.go.jp\/nimh\/yakubutsu\/report\/index.html"},{"key":"e_1_2_12_27_1","unstructured":"Ministry of Health Labour and Welfare [Internet].Promotion of control measures for hepatitis. (in Japanese). [cited 2022 Oct 20]. Available from:https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/kekkaku\u2010kansenshou\/kanen\/index.html"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T07:26:20Z","timestamp":1704525980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/npr2.12346"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12346","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"type":"print","value":"2574-173X"},{"type":"electronic","value":"2574-173X"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"2023-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}